Search results for: NICE

Spotlight on OHE: Assessing Value and Balancing Needs in Health Care

15 December 2011

…quarter of 2011. Two of these considered adopting broader, societal approaches to HTA. At the NICE methods review workshop in Manchester in October, Nancy Devlin participated in a discussion that…

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

1 March 2018

The report addresses the implications of NICE appraising treatments for very rare diseases using a cost-per-QALY gained decision rule of the type used by NICE in its Technology Appraisal Programme…

Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA

17 January 2024

…workshops conducted by NICE felt that health outcomes should always be prioritised. Looking to the future, a recent paper by colleagues at NICE identified four potential options for how NICE…

OHE at ISPOR’s 20th Annual European Congress: Presentations

…NICE HTA of using the EQ-5D-5L and its English value set. Rosie Lovett from NICE outlined the key considerations. Allan Wailoo presented analysis undertaken by the NICE Decision Support Unit…

New Findings: Public Attitudes Towards End-of-Life Treatment in England and Wales

7 December 2012

In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the…

Spotlight on OHE: Innovation, Regulation and Antibiotics

30 September 2014

…reference for pricing in other markets. How NICE expresses the value of medicines can be viewed as the NHS’s way of regulating innovation in prescription medicines. NICE bases its decisions…

New Publication: Opportunity Costs and Local Health Service Spending Decisions – A Qualitative Study from Wales

26 April 2016

…Care Excellence (NICE) recommends a new cost-increasing technology for mandatory use in the NHS as part of its Technology Appraisal (TA) programme. The authors conducted semi-structured interviews with Finance and…

Ethical and Economic Issues in the Appraisal of Medicines for Ultra-rare (or Ultra-orphan) Conditions

13 January 2020

In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct…

From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers

19 January 2016

…it is time that the National Institute for Health and Care Excellence (NICE) revisited its processes or, more specifically, its criteria for making decisions.  In the current austere climate one…